E J Small

Summary

Affiliation: University of California
Country: USA

Publications

  1. ncbi Low dose ketoconazole with replacement doses of hydrocortisone in patients with progressive androgen independent prostate cancer
    Katherine A Harris
    University of California, San Francisco, UCSF Comprehensive Cancer Center, San Francisco, California, USA
    J Urol 168:542-5. 2002
  2. ncbi Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells
    E J Small
    Department of Medicine and Urology, University of California San Francisco Comprehensive Cancer Center, University of California, San Francisco, CA 94115, USA
    J Clin Oncol 18:3894-903. 2000
  3. ncbi Randomized study of three different doses of suramin administered with a fixed dosing schedule in patients with advanced prostate cancer: results of intergroup 0159, cancer and leukemia group B 9480
    Eric J Small
    Comprehensive Cancer Center, University of California San Francisco, 1600 Devisadero Street, Third Floor, San Francisco, CA 94115, USA
    J Clin Oncol 20:3369-75. 2002
  4. ncbi Overview of bladder cancer trials in the Cancer and Leukemia Group B
    Eric J Small
    Department of Medicine, University of California San Francisco, San Francisco, California 94115, USA
    Cancer 97:2090-8. 2003
  5. ncbi Activities and accomplishments of the cancer and leukemia group B genitourinary committee
    Eric J Small
    University of California San Francisco, San Francisco, California, USA
    Clin Cancer Res 12:3596s-600s. 2006
  6. ncbi Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer
    Eric J Small
    UCSF Comprehensive Cancer Center, University of California, San Francisco, 1600 Divisadero St, Box 1711, San Francisco, CA 94115, USA
    J Clin Oncol 24:3089-94. 2006
  7. ncbi Docetaxel in prostate cancer
    E J Small
    Urologic Oncology Program, UCSF Comprehensive Cancer Center, 1600 Divisadero St, 3rd Floor, San Francisco, CA 94115, USA
    Anticancer Drugs 12:S17-20. 2001
  8. ncbi Serum prostate-specific antigen decline as a marker of clinical outcome in hormone-refractory prostate cancer patients: association with progression-free survival, pain end points, and survival
    E J Small
    University of California, San Francisco, CA, USA
    J Clin Oncol 19:1304-11. 2001
  9. ncbi Combined analysis of two multicenter, randomized, placebo-controlled studies of pamidronate disodium for the palliation of bone pain in men with metastatic prostate cancer
    Eric J Small
    UCSF Comprehensive Cancer Center, University of California, San Francisco, 1600 Divisadero St, A718, San Francisco, CA 94115, USA
    J Clin Oncol 21:4277-84. 2003
  10. ncbi Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: a phase III trial (CALGB 9583)
    Eric J Small
    UCSF Comprehensive Cancer Center, University of California San Francisco, 1600 Divisadero St, Room A 718, San Francisco, CA 94115, USA
    J Clin Oncol 22:1025-33. 2004

Detail Information

Publications113 found, 100 shown here

  1. ncbi Low dose ketoconazole with replacement doses of hydrocortisone in patients with progressive androgen independent prostate cancer
    Katherine A Harris
    University of California, San Francisco, UCSF Comprehensive Cancer Center, San Francisco, California, USA
    J Urol 168:542-5. 2002
    ..CONCLUSIONS: The regimen of low dose ketoconazole with replacement doses of hydrocortisone is well tolerated and has moderate activity in patients with progressive androgen independent prostate cancer...
  2. ncbi Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells
    E J Small
    Department of Medicine and Urology, University of California San Francisco Comprehensive Cancer Center, University of California, San Francisco, CA 94115, USA
    J Clin Oncol 18:3894-903. 2000
    ..Sequential phase I and phase II trials were performed to determine the safety and efficacy of Provenge and to assess its capacity to break immune tolerance to the normal tissue antigen PAP...
  3. ncbi Randomized study of three different doses of suramin administered with a fixed dosing schedule in patients with advanced prostate cancer: results of intergroup 0159, cancer and leukemia group B 9480
    Eric J Small
    Comprehensive Cancer Center, University of California San Francisco, 1600 Devisadero Street, Third Floor, San Francisco, CA 94115, USA
    J Clin Oncol 20:3369-75. 2002
    ..To test the hypothesis that the efficacy and toxicity of suramin in the treatment of patients with hormone-refractory prostate cancer was dose dependent...
  4. ncbi Overview of bladder cancer trials in the Cancer and Leukemia Group B
    Eric J Small
    Department of Medicine, University of California San Francisco, San Francisco, California 94115, USA
    Cancer 97:2090-8. 2003
    ..Novel agents, including arsenic trioxide and trastuzumab (Herceptin; Genentech, Inc., South San Francisco, CA), are being evaluated as secondline therapy in patients with advanced TCC who have disease progression after frontline therapy...
  5. ncbi Activities and accomplishments of the cancer and leukemia group B genitourinary committee
    Eric J Small
    University of California San Francisco, San Francisco, California, USA
    Clin Cancer Res 12:3596s-600s. 2006
    ..In addition to these areas, future work of the committee will include further development of therapy for earlier-stage prostate cancer patients and bladder cancer patients...
  6. ncbi Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer
    Eric J Small
    UCSF Comprehensive Cancer Center, University of California, San Francisco, 1600 Divisadero St, Box 1711, San Francisco, CA 94115, USA
    J Clin Oncol 24:3089-94. 2006
    ..A phase III study was undertaken to evaluate the safety and efficacy of sipuleucel-T in a placebo-controlled study...
  7. ncbi Docetaxel in prostate cancer
    E J Small
    Urologic Oncology Program, UCSF Comprehensive Cancer Center, 1600 Divisadero St, 3rd Floor, San Francisco, CA 94115, USA
    Anticancer Drugs 12:S17-20. 2001
    ..In the future, the efficacy of docetaxel plus estramustine may be enhanced by adding agents to this regimen...
  8. ncbi Serum prostate-specific antigen decline as a marker of clinical outcome in hormone-refractory prostate cancer patients: association with progression-free survival, pain end points, and survival
    E J Small
    University of California, San Francisco, CA, USA
    J Clin Oncol 19:1304-11. 2001
    ..The purpose of this study was to determine whether posttreatment declines in PSA were associated with clinical measures of improvement in a randomized phase III trial of suramin plus hydrocortisone versus placebo plus hydrocortisone...
  9. ncbi Combined analysis of two multicenter, randomized, placebo-controlled studies of pamidronate disodium for the palliation of bone pain in men with metastatic prostate cancer
    Eric J Small
    UCSF Comprehensive Cancer Center, University of California, San Francisco, 1600 Divisadero St, A718, San Francisco, CA 94115, USA
    J Clin Oncol 21:4277-84. 2003
    ..Pain is common in these patients. The purpose of this study was to evaluate the effect of an intravenous bisphosphonate, pamidronate disodium, on pain control in metastatic prostate cancer patients...
  10. ncbi Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: a phase III trial (CALGB 9583)
    Eric J Small
    UCSF Comprehensive Cancer Center, University of California San Francisco, 1600 Divisadero St, Room A 718, San Francisco, CA 94115, USA
    J Clin Oncol 22:1025-33. 2004
    ..Thereafter, adrenal androgen ablation with agents such as ketoconazole (K) is commonly utilized. The therapeutic effect of AAWD alone was compared with simultaneous AAWD and K therapy...
  11. ncbi Prospective trial of the herbal supplement PC-SPES in patients with progressive prostate cancer
    E J Small
    University of California at San Francisco, San Francisco, CA, USA
    J Clin Oncol 18:3595-603. 2000
    ..PC-SPES is an herbal supplement for which there are anecdotal reports of anti-prostate cancer activity. This phase II study was undertaken to assess the efficacy and toxicity of PC-SPES in prostate cancer patients...
  12. ncbi A phase II pilot study of KW-2189 in patients with advanced renal cell carcinoma
    E J Small
    UCSF Comprehensive Cancer Center, University of California, San Francisco 94115, USA
    Invest New Drugs 18:193-7. 2000
    ..KW-2189 is a semi-synthetic, water-soluble analog of duocarmycin B2, a new class of potent antitumor antibiotics produced by streptomyces, with improved in vitro antitumor potency...
  13. ncbi A pilot trial of CTLA-4 blockade with human anti-CTLA-4 in patients with hormone-refractory prostate cancer
    Eric J Small
    UCSF Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA 94115, USA
    Clin Cancer Res 13:1810-5. 2007
    ....
  14. ncbi An update on prostate cancer research
    E J Small
    University of California, San Francisco, Comprehensive Cancer Center, 94115, USA
    Curr Opin Oncol 12:265-72. 2000
    ..Finally, treatment strategies for patients with androgen-independent disease have also expanded, although novel therapies are required to improve survival in this group of patients...
  15. ncbi Granulocyte macrophage colony-stimulating factor--secreting allogeneic cellular immunotherapy for hormone-refractory prostate cancer
    Eric J Small
    University of California, San Francisco, Comprehensive Cancer Center, San Francisco, California 94115, USA
    Clin Cancer Res 13:3883-91. 2007
    ..The immunotherapy, based on the GVAX platform, is a combination of two prostate carcinoma cell lines modified with the granulocyte macrophage colony-stimulating factor (GM-CSF) gene...
  16. ncbi New treatment strategies in advanced prostate cancer
    E J Small
    Department of Medicine, University of California San Francisco, USA
    Radiol Clin North Am 38:203-11, ix-x. 2000
    ....
  17. ncbi Suramin therapy for patients with symptomatic hormone-refractory prostate cancer: results of a randomized phase III trial comparing suramin plus hydrocortisone to placebo plus hydrocortisone
    E J Small
    University of California at San Francisco Comprehensive Cancer Center, San Francisco 94115, USA
    J Clin Oncol 18:1440-50. 2000
    ..A prospective randomized clinical trial was designed to evaluate pain and opioid analgesic intake as surrogates for antitumor response in HRPC patients with significant, opioid analgesic-dependent pain...
  18. ncbi Androgen deprivation therapy for patients with clinically localized (stages T1 to T3) prostate cancer and for patients with biochemical recurrence after radical prostatectomy
    G D Grossfeld
    Department of Urology, University of California, San Francisco/Mount Zion Cancer Center, San Francisco, California 94143-0738, USA
    Urology 58:56-64. 2001
    ..The role of ADT in patients with clinically localized and recurrent prostate cancer, whether it is delivered in a continuous or intermittent fashion, must be determined in randomized, prospective trials...
  19. ncbi Prostate cancer update
    Jonathan Rosenberg
    Comprehensive Cancer Center, University of California-San Francisco, 1600 Divisadero Street, 3rd Floor, San Francisco, CA 94115, USA
    Curr Opin Oncol 15:217-21. 2003
    ..In addition, the role of bisphosphonates in patients with bone metastasis was established...
  20. ncbi Vascular endothelial growth factor and basic fibroblast growth factor urine levels as predictors of outcome in hormone-refractory prostate cancer patients: a cancer and leukemia group B study
    R A Bok
    University of California at San Francisco, Comprehensive Cancer Center, 94143 0324, USA
    Cancer Res 61:2533-6. 2001
    ..These results support the notion that certain peptide growth factor-mediated, mitogenic pathways are important in HRPC and that their levels can predict outcome...
  21. ncbi Intermittent androgen deprivation: update of cycling characteristics in patients without clinically apparent metastatic prostate cancer
    G D Grossfeld
    Department of Urology, University of California, San Francisco, School of Medicine, San Francisco, California 94143-0738, USA
    Urology 58:240-5. 2001
    ..Longer follow-up with more patients failing IAD will be required before clear patterns of failure emerge in these patients...
  22. ncbi Docetaxel, estramustine, plus trastuzumab in patients with metastatic androgen-independent prostate cancer
    E J Small
    Urologic Oncology Program, University of California, San Francisco Comprehensive Cancer Center, San Francisco, CA 94143-1711, USA
    Semin Oncol 28:71-6. 2001
    ..The response data are too preliminary for speculation about the relative benefits of this 3-drug regimen compared with the combination of only docetaxel and estramustine in this clinical setting...
  23. ncbi HER2 protein expression and gene amplification in androgen-independent prostate cancer
    D M Reese
    Urologic Oncology Program, Division of Hematology-Oncology, Comprehensive Cancer Center, University of California, 2356 Sutter St, 5th Floor, San Francisco, CA 94115, USA
    Am J Clin Pathol 116:234-9. 2001
    ..Two (6%) of 36 specimens had gene amplification by FISH. These data suggest that HER2 protein overexpression and gene amplification are relatively uncommon in AIPC...
  24. ncbi Paclitaxel, estramustine phosphate, and carboplatin in patients with advanced prostate cancer
    W K Kelly
    Genitourinary Oncology Service, Division of Solid Tumor, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021 6007, USA
    J Clin Oncol 19:44-53. 2001
    ..To determine the safety and activity of weekly paclitaxel in combination with estramustine and carboplatin (TEC) in patients with advanced prostate cancer...
  25. ncbi Immunotherapy for prostate cancer
    B I Rini
    University of California at San Francisco Comprehensive Cancer Center, 1600 Divisidero Street, 3rd Floor, San Francisco, CA 94115, USA
    Curr Oncol Rep 3:418-23. 2001
    ..Many approaches in prostate cancer have demonstrated successful induction of the desired immune response. Limited clinical success has also been seen...
  26. ncbi Prostate cancer update
    Brian I Rini
    University of California at San Francisco Comprehensive Cancer Center, San Francisco, California 94115, USA
    Curr Opin Oncol 14:286-91. 2002
    ..This article reviews the major advances in prostate cancer published between November 1, 2000, and October 31, 2001...
  27. ncbi Neoadjuvant strategies for prostate cancer prior to radical prostatectomy
    Maxwell V Meng
    Department of Urology and the Comprehensive Cancer Center, University of California San Francisco, CA 94115-3006, USA
    Semin Urol Oncol 20:10-8. 2002
    ..Novel neoadjuvant hormonal and chemotherapeutic regimens are under investigation and may improve outcomes for patients undergoing radical prostatectomy...
  28. ncbi Phase I study of ixabepilone, mitoxantrone, and prednisone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel-based therapy: a study of the department of defense prostate cancer clinical trials consortium
    Jonathan E Rosenberg
    Department of Medicine, University of California San Franscisco, Helen Diller Family Comprehensive Cancer Center, 1600 Divisadero St, Box 1711, San Francisco, CA 94115, USA
    J Clin Oncol 27:2772-8. 2009
    ..Mitoxantrone plus prednisone and ixabepilone each have modest activity as second-line chemotherapy in docetaxel-refractory castration-resistant prostate cancer (CRPC) patients. Clinical noncrossresistance was previously observed...
  29. ncbi A phase II study of gemcitabine and capecitabine in metastatic renal cancer: a report of Cancer and Leukemia Group B protocol 90008
    Walter M Stadler
    Section of Hematology Oncology, Department of Medicine, University of Chicago Medical Center, Chicago, Illinois 60637, USA
    Cancer 107:1273-9. 2006
    ..The objective of this study was to verify previous reports of activity with gemcitabine plus a fluoropyrimidine in patients with metastatic renal cell cancer in a multiinstitutional setting...
  30. ncbi Immunotherapy for prostate cancer
    Lawrence Fong
    Department of Medicine, University of California, San Francisco, CA 94143, USA
    Semin Oncol 30:649-58. 2003
    ..Immunotherapy trials have already demonstrated evidence of not only immunogenicity, but also clinical efficacy, and future studies will be directed at capitalizing on these findings...
  31. ncbi Second-line hormonal therapy for advanced prostate cancer: a shifting paradigm
    E J Small
    Department of Medicine, University of California, San Francisco 94115, USA
    J Clin Oncol 15:382-8. 1997
    ..To discuss the evolution of new concepts in the Use of second-line hormonal therapy for patients with progressive prostate cancer despite androgen deprivation...
  32. ncbi Therapy of advanced prostate cancer with granulocyte macrophage colony-stimulating factor
    E J Small
    Department of Medicine, University of California, San Francisco 94115, USA
    Clin Cancer Res 5:1738-44. 1999
    ....
  33. ncbi Pyrazoloacridine for the treatment of hormone-refractory prostate cancer
    E J Small
    Department of Medicine, University of California, San Francisco, USA
    Cancer Invest 16:456-61. 1998
    ..If PSA is used as a marker of response, single-agent PZA appears to lack efficacy in the treatment of HRPC. However, the one unambiguous response, and the favorable toxicity profile observed, may warrant further evaluation of this agent...
  34. ncbi Phase II study of bortezomib in patients with previously treated advanced urothelial tract transitional cell carcinoma: CALGB 90207
    J E Rosenberg
    Division of Hematology and Oncology, University of California, San Francisco Cancer Center, San Francisco, CA 94115, USA
    Ann Oncol 19:946-50. 2008
    ..Response rates to second-line chemotherapy for advanced UC are low and response duration is short. Bortezomib is a proteasome inhibitor with preclinical activity against UC...
  35. ncbi A phase II trial of imatinib mesylate in patients with biochemical relapse of prostate cancer after definitive local therapy
    Amy M Lin
    University of California/San Francisco, San Francisco, CA 94115, USA
    BJU Int 98:763-9. 2006
    ....
  36. ncbi Prior estrogen therapy as a predictor of response to subsequent estramustine-based chemotherapy in patients with androgen-independent prostate cancer
    Jorge A Garcia
    Department of Medicine, University of California San Francisco Comprehensive Cancer Center, USA
    Clin Prostate Cancer 4:113-7. 2005
    ..To determine whether previous response to second-line estrogen therapy would predict subsequent response to EMP-based chemotherapy, a retrospective study was conducted...
  37. ncbi CTLA4 blockade expands FoxP3+ regulatory and activated effector CD4+ T cells in a dose-dependent fashion
    Brian Kavanagh
    Department of Microbiology and Immunology, Division of Hematology Oncology, University of California, San Francisco, CA 94143, USA
    Blood 112:1175-83. 2008
    ..Our results also suggest that CTLA4 may inhibit Treg proliferation similar to its role on effector T cells. This study is registered at http://www.clinicaltrials.gov/ct2/show/NCT00064129, registry number NCT00064129...
  38. ncbi Clinical response to therapy targeted at vascular endothelial growth factor in metastatic renal cell carcinoma: impact of patient characteristics and Von Hippel-Lindau gene status
    Brian I Rini
    Department of Medicine, The University of California San Francisco, San Francisco, California, USA
    BJU Int 98:756-62. 2006
    ..To describe the relationship among patient characteristics, Von Hippel-Lindau (VHL) gene status and clinical outcome in metastatic renal cell carcinoma (RCC) in patients receiving vascular endothelial growth factor (VEGF)-targeted therapy...
  39. ncbi Prostate-specific antigen in prostate cancer: a case study in the development of a tumor marker to monitor recurrence and assess response
    Eric J Small
    Comprehensive Cancer Center, University of California, San Francisco, CA, USA
    Semin Oncol 29:264-73. 2002
    ....
  40. ncbi Androgen deprivation therapy in locally advanced and metastatic prostate cancer
    C J Ryan
    Department of Medicine and UCSF Comprehensive Cancer Center, University of California, San Francisco, CA 94143, USA
    Minerva Urol Nefrol 58:119-26. 2006
    ..In virtually all analyses, patients with high-risk features benefited from early AD when compared to deferred therapy. Consideration of AD is therefore warranted early in the clinical course of high-risk patients...
  41. ncbi Secondary hormonal manipulation of prostate cancer
    K A Harris
    University of California, San Francisco Comprehensive Cancer Center, 1600 Divisadero Street, 3rd Floor, San Francisco, CA 94115, USA
    Curr Urol Rep 2:224-30. 2001
    ..This approach is predicated on the recognition that HRPC is a heterogeneous disease, and some patients may respond to alternative hormonal interventions despite the presence of castrate levels of testosterone...
  42. ncbi The case for secondary hormonal therapies in the chemotherapy age
    Eric J Small
    Urologic Oncology Program, UCSF Comprehensive Cancer Center, University of California San Francisco, 1600 Divisadero Street, San Francisco, CA 94115, USA
    J Urol 176:S66-71. 2006
    ..Despite this fact numerous therapies are available that target the interaction of androgen and androgen receptor in the castrate testosterone milieu and many clinical investigations are under way in this area...
  43. ncbi High risk biochemical relapse and the timing of androgen deprivation therapy
    Charles J Ryan
    Department of Medicine and UCSF Comprehensive Cancer Center, University of California San Francisco, 1600 Divisadero Street, San Francisco, CA 94115, USA
    J Urol 176:S61-5. 2006
    ..We offer guidance on its use in patients with prostate specific antigen recurrence only...
  44. ncbi Sipuleucel-T (APC8015) for prostate cancer
    Rosendo So-Rosillo
    Hematology Oncology, University of California, 505 Parnassus Avenue, M1286 San Francisco, CA 94143 1270, USA
    Expert Rev Anticancer Ther 6:1163-7. 2006
    ..Clinical trials are ongoing or are being developed to evaluate sipuleucel-T in various prostate cancer disease states and in combination with other treatment modalities...
  45. ncbi Clinical trials in patients with biochemically relapsed prostate cancer
    Amy M Lin
    UCSF Comprehensive Cancer Center, University of California/San Francisco, San Francisco, CA 94115, USA
    BJU Int 97:905-10. 2006
    ..Finally there are two papers from Australia describing the use of positron emission tomography in renal cancer and in prostate cancer...
  46. ncbi Intermittent chemotherapy for metastatic hormone refractory prostate cancer
    Amy M Lin
    UCSF Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA 94115, USA
    Crit Rev Oncol Hematol 61:243-54. 2007
    ....
  47. ncbi Expression of insulin-like growth factor-1 receptor in local and metastatic prostate cancer
    Charles J Ryan
    Department of Medicine, UCSF Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA 94115, USA
    Urol Oncol 25:134-40. 2007
    ..Despite this targeting, there are conflicting data on the presence of this receptor in human tumor samples, largely because of differences in technique...
  48. ncbi Reduced incidence of bony metastasis at initial prostate cancer diagnosis: data from CaPSURE
    Charles J Ryan
    Department of Medicine, and UCSF Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA 94143, USA
    Urol Oncol 24:396-402. 2006
    ..This study describes features that characterize patients with M+ compared to those diagnosed with M0 disease...
  49. ncbi Adrenal androgen levels as predictors of outcome in prostate cancer patients treated with ketoconazole plus antiandrogen withdrawal: results from a cancer and leukemia group B study
    Charles J Ryan
    Urologic Oncology Program, University of California, San Francisco, California 94143, USA
    Clin Cancer Res 13:2030-7. 2007
    ..Ketoconazole is used as an inhibitor of adrenal androgen synthesis in men with androgen-independent prostate cancer. This study analyzes the relationship between pretreatment androgen levels and outcome following ketoconazole treatment...
  50. ncbi Evaluation and significance of circulating epithelial cells in patients with hormone-refractory prostate cancer
    Jorge A Garcia
    Department of Medicine, University of California San Francisco, San Francisco, CA, USA
    BJU Int 99:519-24. 2007
    ....
  51. ncbi Prostate cancer update: 2006
    Amy M Lin
    UCSF Comprehensive Cancer Center, University of California, San Francisco, California 94115, USA
    Curr Opin Oncol 19:229-33. 2007
    ..This review highlights the most important developments in the diagnosis, prevention, and treatment of prostate cancer published in the medical literature over the past year...
  52. ncbi The selection of hormonal therapy in prostate cancer: who, when, and for how long?
    Charles J Ryan
    Department of Medicine, UCSF Comprehensive Cancer Center, University of California San Francisco, 1600 Divisadero St, San Francisco, CA 94143, USA
    J Natl Compr Canc Netw 2:261-8. 2004
    ....
  53. ncbi Potentiating endogenous antitumor immunity to prostate cancer through combination immunotherapy with CTLA4 blockade and GM-CSF
    Lawrence Fong
    Division of Hematology Oncology, University of California, San Francisco, San Francisco, California 94143, USA
    Cancer Res 69:609-15. 2009
    ....
  54. ncbi Anti-cytotoxic T-lymphocyte antigen-4 antibody: the first in an emerging class of immunomodulatory antibodies for cancer treatment
    Lawrence Fong
    Department of Medicine, Division of Hematology Oncology, University of California at San Francisco, San Francisco, CA 94143 0511, USA
    J Clin Oncol 26:5275-83. 2008
    ..Antibodies (ipilimumab and tremelimumab) targeting cytotoxic T-lymphocyte antigen-4 (CTLA-4), an inhibitory molecule on T cells, represent the vanguard of these new drugs...
  55. ncbi Prostate cancer update: 2007
    Amy M Lin
    UCSF Comprehensive Cancer Center, University of California, San Francisco, California 94115, USA
    Curr Opin Oncol 20:294-9. 2008
    ..The present review highlights the year's most important developments in the risk assessment, diagnosis, and treatment of prostate cancer...
  56. ncbi The mechanism of action of estrogen in castration-resistant prostate cancer: clues from hormone levels
    Rahul Aggarwal
    Urologic Oncology Program, Department of Medicine, UCSF Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA 94115, USA
    Clin Genitourin Cancer 7:E71-6. 2009
    ..This current analysis reports the relationship of change in adrenal androgen levels and prostate-specific antigen (PSA) response in patients with CRPC treated with estrogen therapy...
  57. ncbi Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group
    Howard I Scher
    Genitourinary Oncology Service, Department of Medicine, Sidney Kimmel Center for Prostate and Urologic Cancers, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10065, USA
    J Clin Oncol 26:1148-59. 2008
    ..To update eligibility and outcome measures in trials that evaluate systemic treatment for patients with progressive prostate cancer and castrate levels of testosterone...
  58. ncbi A pilot dose-escalation study of the effects of nordihydroguareacetic acid on hormone and prostate specific antigen levels in patients with relapsed prostate cancer
    Charles J Ryan
    Department of Medicine and the corrected UCSF Comprehensive Cancer Center, University of California San Francisco, CA 94143, USA
    BJU Int 101:436-9. 2008
    ....
  59. ncbi Phase II study of ketoconazole plus granulocyte-macrophage colony-stimulating factor for prostate cancer: effect of extent of disease on outcome
    Charles J Ryan
    Urologic Oncology Program, University of California San Francisco Comprehensive Cancer Center, University of California San Francisco, San Francisco, California 94115, USA
    J Urol 178:2372-6; discussion 2377. 2007
    ..The efficacy of ketoconazole plus the immunostimulatory cytokine granulocyte-macrophage colony-stimulating factor was prospectively evaluated in patients with castration resistant prostate cancer with and without metastases...
  60. ncbi Androgen-response elements in hormone-refractory prostate cancer: implications for treatment development
    Andrew C Hsieh
    Department of Medicine, and UCSF Comprehensive Cancer Center, University of California San Francisco, 94143, USA
    Lancet Oncol 8:933-9. 2007
    ..We discuss the effects of bona-fide downstream targets of the androgen receptor on cellular proliferation, evasion of apoptosis, and angiogenesis, and consider the clinical potential of these targets...
  61. ncbi A phase I trial of docetaxel/estramustine/imatinib in patients with hormone-refractory prostate cancer
    Amy M Lin
    UCSF Comprehensive Cancer Center, University of California, San Francisco, CA 94115, USA
    Clin Genitourin Cancer 5:323-8. 2007
    ..Imatinib inhibits the platelet-derived growth factor receptor that is expressed in prostate cancer and is synergistic with taxanes in preclinical prostate cancer models...
  62. ncbi Activity of second-line chemotherapy in docetaxel-refractory hormone-refractory prostate cancer patients : randomized phase 2 study of ixabepilone or mitoxantrone and prednisone
    Jonathan E Rosenberg
    Department of Medicine, University of California at San Francisco, Comprehensive Cancer Center, San Francisco, California, USA
    Cancer 110:556-63. 2007
    ..This randomized, noncomparative, multicenter, clinical trial evaluated ixabepilone or mitoxantrone/prednisone (MP) as second-line chemotherapy for taxane-refractory, hormone-refractory, prostate cancer (HRPC)...
  63. ncbi Phase I dose escalation and pharmacokinetic study of AZD2171, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinase, in patients with hormone refractory prostate cancer (HRPC)
    Charles J Ryan
    Urologic Oncology Program, UCSF Comprehensive Cancer Center, 1600 Divisadero 3rd Floor, San Francisco, CA, USA
    Invest New Drugs 25:445-51. 2007
    ..While further study is indicated, careful attention must be paid to the novel toxicities of this agent with prolonged dosing...
  64. ncbi Immunotherapy for prostate cancer
    Lawrence Fong
    University of California, San Francisco, San Francisco, CA 94143 0511, USA
    Curr Oncol Rep 9:226-33. 2007
    ..Emerging trials have demonstrated that immunotherapy may generate not only immune responses in patients but also clinical responses. Future studies will be directed at capitalizing on these findings...
  65. ncbi Phase I clinical trial of the CYP17 inhibitor abiraterone acetate demonstrating clinical activity in patients with castration-resistant prostate cancer who received prior ketoconazole therapy
    Charles J Ryan
    Urologic Oncology Program, University of California, San Francisco, San Francisco, CA 94115, USA
    J Clin Oncol 28:1481-8. 2010
    ..This phase I dose-escalation study of abiraterone acetate evaluated safety, pharmacokinetics, and effects on steroidogenesis and prostate-specific antigen (PSA) levels in men with CPRC with or without prior ketoconazole therapy...
  66. ncbi Immunotherapy for prostate cancer
    Lawrence Fong
    University of California San Francisco, 513 Parnassus Avenue, San Francisco, CA 94143, USA
    Curr Urol Rep 7:239-46. 2006
    ..Emerging trials have demonstrated that immunotherapy may not only generate immune responses in patients, but also clinical responses. Future studies will be directed at capitalizing on these findings...
  67. ncbi A retrospective evaluation of second-line chemotherapy response in hormone-refractory prostate carcinoma: second line taxane-based therapy after first-line epothilone-B analog ixabepilone (BMS-247550) therapy
    Jonathan E Rosenberg
    Division of Hematology Oncology, University of California San Francisco, San Francisco, California 94115, USA
    Cancer 106:58-62. 2006
    ..Clinical cross-resistance of ixabepilone and taxanes in HRPC is unknown...
  68. ncbi Role of secondary hormonal therapy in the management of recurrent prostate cancer
    Charles J Ryan
    Urologic Oncology Program, University of California San Francisco Comprehensive Cancer Center, University of California San Francisco, San Francisco, California 94143, USA
    Urology 62:87-94. 2003
    ..This article reviews the clinical trial data for these various agents and discusses their role in the management of patients with advanced prostate cancer...
  69. ncbi Second-line chemotherapy for hormone-refractory prostate cancer: has the time come?
    Jonathan E Rosenberg
    University of California at San Francisco, Comprehensive Cancer Center, San Francisco, CA 94115, USA
    Clin Prostate Cancer 3:122-4. 2004
    ..Finding new agents that are active in the second-line setting and identifying relevant outcome variables and predictive pretreatment variables are crucial in improving survival and quality of life for this patient population...
  70. ncbi Practice and progress in kidney cancer: methodology for novel drug development
    Brian I Rini
    Comprehensive Cancer Center, University of California San Francisco, San Francisco, California 94115, USA
    J Urol 171:2115-21. 2004
    ..Furthermore, we describe new paradigms for the evaluation of novel agents to optimize the yield of clinical research in RCC...
  71. ncbi A phase II trial of R115777, an oral farnesyl transferase inhibitor, in patients with advanced urothelial tract transitional cell carcinoma
    Jonathan E Rosenberg
    Department of Medicine, University of California, San Francisco, California 94115, USA
    Cancer 103:2035-41. 2005
    ..R115777 is a potent farnesyl transferase inhibitor and has significant antitumor effects in vitro and in vivo...
  72. ncbi Progress in detection and treatment of prostate cancer
    Charles J Ryan
    Department of Medicine, UCSF Comprehensive Cancer Center, University of California, San Francisco, California, USA
    Curr Opin Oncol 17:257-60. 2005
    ..The purpose of this review is to highlight the most important developments in the diagnosis, prevention, and management of prostate cancer reported in the past year that have been published in the medical literature...
  73. ncbi Cancer and Leukemia Group B 90206: A randomized phase III trial of interferon-alpha or interferon-alpha plus anti-vascular endothelial growth factor antibody (bevacizumab) in metastatic renal cell carcinoma
    Brian I Rini
    University of California at San Francisco, San Francisco, California 94115, USA
    Clin Cancer Res 10:2584-6. 2004
    ..A Phase III trial is now being conducted randomizing untreated, metastatic clear cell RCC patients to IFN-alpha alone or IFN-alpha plus Avastin...
  74. ncbi The potential for prostate cancer immunotherapy
    Brian I Rini
    University of California San Francisco UCSF Comprehensive Cancer Center, USA
    Crit Rev Oncol Hematol 46:S117-25. 2003
    ..Many approaches in prostate cancer have demonstrated successful induction of the desired immune response. Limited clinical success has also been seen...
  75. ncbi Bloodborne biomolecular markers in prostate cancer development and progression
    Robert A Bok
    Department of Medicine, Urologic Oncology Program, Comprehensive Cancer Center, University of California San Francisco, California 94143, USA
    Nat Rev Cancer 2:918-26. 2002
    ..But imperfect correlation with cancer hinders the usefulness of PSA. The elucidation and validation of new biological markers of prostate cancer should aid detection, and improve the application of the available therapeutics...
  76. ncbi Phase II trial of carboplatin and paclitaxel in cisplatin-pretreated advanced transitional cell carcinoma: a Southwest Oncology Group study
    Ulka N Vaishampayan
    Division of Hematology Oncology, Department of Medicine, Wayne State University Medical Center, Detroit, Michigan 48201, USA
    Cancer 104:1627-32. 2005
    ..The purpose of the study was to assess the efficacy and toxicity of carboplatin and paclitaxel administered every 3 weeks in patients with advanced urothelial carcinoma, previously treated with cisplatin-based therapy...
  77. ncbi Early versus delayed androgen deprivation for prostate cancer: new fuel for an old debate
    Charles J Ryan
    UCSF Comprehensive Cancer Center, 1600 Divisadero St, San Francisco CA 94143, USA
    J Clin Oncol 23:8225-31. 2005
    ..Consideration of AD is therefore warranted early in the clinical course of high-risk patients...
  78. ncbi Time to disease progression to evaluate a novel protein kinase C inhibitor, UCN-01, in renal cell carcinoma
    Brian I Rini
    UCSF Comprehensive Cancer Center, The University of California San Francisco, 1600 Divisadero, Rm A717, San Francisco, CA 94115, USA
    Cancer 101:90-5. 2004
    ..Given the historically low objective response rate in RCC, time to disease progression (TTP) as an alternative endpoint was employed to evaluate the antitumor activity of UCN-01 in RCC...
  79. ncbi Prostate-specific antigen kinetics as a measure of the biologic effect of granulocyte-macrophage colony-stimulating factor in patients with serologic progression of prostate cancer
    Brian I Rini
    University of California San Francisco Comprehensive Cancer Center, San Francisco, CA 94115, USA
    J Clin Oncol 21:99-105. 2003
    ....
  80. ncbi Nomogram for overall survival of patients with progressive metastatic prostate cancer after castration
    Oren Smaletz
    Genitourinary Oncology Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 20:3972-82. 2002
    ..The information is useful to assess prognosis, guide treatment selection, and design clinical trials...
  81. ncbi Secondary hormonal manipulation of prostate cancer
    Eric J Small
    Urologic Oncology Program, University of California, San Francisco Comprehensive Cancer Center, San Francisco, CA 94115, USA
    Semin Urol Oncol 20:24-30. 2002
    ..This approach is predicated on the recognition that HRPC is a heterogeneous disease, and some patients may respond to alternative hormonal interventions despite the presence of castrate levels of testosterone...
  82. ncbi Hormone-refractory Prostate Cancer
    Brian I Rini
    University of California at San Francisco Comprehensive Cancer Center, 1600 Divisadero Avenue, 3rd Floor, 94115, USA
    Curr Treat Options Oncol 3:437-46. 2002
    ..Furthermore, the application of chemotherapeutic regimens has provided viable treatment options for patients with HRPC...
  83. ncbi Biology and clinical development of vascular endothelial growth factor-targeted therapy in renal cell carcinoma
    Brian I Rini
    University of California San Francisco Comprehensive Cancer Center, CA, USA
    J Clin Oncol 23:1028-43. 2005
    ..To review the biology of renal cell carcinoma (RCC) leading to vascular endothelial growth factor (VEGF) overexpression and the clinical results of VEGF blockade in metastatic RCC...
  84. ncbi Hormonal treatment for prostate cancer
    K A Harris
    UCSF Comprehensive Cancer Center, 1600 Divisadero Street, 3rd Floor, San Francisco, CA 94115, USA
    Expert Opin Investig Drugs 10:493-510. 2001
    ..It has been hoped that the development of alternative hormonal interventions might lead to both enhanced antitumour efficacy as well as improvements in side effect profile...
  85. ncbi The evolving role of androgen deprivation therapy in the management of prostate cancer
    M R Cooperberg
    Department of Urology, UCSF/Mt Zion Comprehensive, Cancer Center, University of California, San Francisco, CA 94115-1711, USA
    Minerva Urol Nefrol 55:219-38. 2003
    ..Finally, contemporary practice pattern data suggest that use of ADT is increasing across patient risk groups, both in contexts where such therapy is well supported by current evidence and in others where it is not...
  86. ncbi The impact of prior radical prostatectomy in men with metastatic castration recurrent prostate cancer: a pooled analysis of 9 Cancer and Leukemia Group B Trials
    Susan Halabi
    Department of Biostatistics and Bioinformatics, Duke University Medical Center, Durham, North Carolina 27705, USA
    J Urol 177:531-4. 2007
    ....
  87. ncbi Antigen-presenting cells 8015 (Provenge) in patients with androgen-dependent, biochemically relapsed prostate cancer
    Garth Beinart
    Department of Hematology/Oncology, M. D. Anderson Cancer Center, USA
    Clin Prostate Cancer 4:55-60. 2005
    ..Further manipulations of host immunity may be required to achieve a significant antitumor effect...
  88. ncbi Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer
    Susan Halabi
    Department of Biostatistics and Bioinformatics and CALGB Statistical Center, Duke University Medical Center, Durham, NC 27710, USA
    J Clin Oncol 21:1232-7. 2003
    ..To develop and validate a model that can be used to predict the overall survival probability among metastatic hormone-refractory prostate cancer patients (HRPC)...
  89. ncbi Absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: data from Southwest Oncology Group Trial 9346 (INT-0162)
    Maha Hussain
    University of Michigan, Ann Arbor, MI, USA
    J Clin Oncol 24:3984-90. 2006
    ..2 ng/mL or less. CONCLUSION: A PSA of 4 ng/mL or less after 7 months of AD is a strong predictor of survival. This data should be used to tailor future trial design for D2 prostate cancer...
  90. ncbi Safety and biological activity of repeated doses of recombinant human Flt3 ligand in patients with bone scan-negative hormone-refractory prostate cancer
    Celestia S Higano
    University of Washington Medical Center, Seattle, Washington 98109, USA
    Clin Cancer Res 10:1219-25. 2004
    ..In the first cycle, patients were randomized to FL or placebo. All patients received open-label FL during the next five courses. DC, anti-FL antibody, and PSA levels were measured every 15 days to assess biological activity...
  91. ncbi von Hippel-Lindau gene status and response to vascular endothelial growth factor targeted therapy for metastatic clear cell renal cell carcinoma
    Toni K Choueiri
    Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    J Urol 180:860-5; discussion 865-6. 2008
    ..The von Hippel-Lindau (VHL) gene is often inactivated (by mutation or promoter hypermethylation) in renal cell carcinoma but the relation to therapeutic outcome is unclear...
  92. ncbi Phase 1/2 dose-escalation study of a GM-CSF-secreting, allogeneic, cellular immunotherapy for metastatic hormone-refractory prostate cancer
    Celestia S Higano
    Department of Oncology, University of Washington Seattle, Seattle, Washington, USA
    Cancer 113:975-84. 2008
    ..The immunotherapy, based on the GVAX platform, consisted of 2 allogeneic prostate-carcinoma cell lines modified to secrete granulocyte-macrophage-colony-stimulating factor (GM-CSF)...
  93. ncbi Treatment of biochemical recurrence of prostate cancer with granulocyte-macrophage colony-stimulating factor secreting, allogeneic, cellular immunotherapy
    Walter J Urba
    Earle A Chiles Research Institute, Providence Portland Medical Center, Portland, Oregon 97213, USA
    J Urol 180:2011-7; discussion 2017-8. 2008
    ..This phase I-II study evaluated the safety, clinical activity and immunogenicity of an immunotherapy developed from human prostate cancer cell lines (PC-3 and LNCaP) modified to secrete granulocyte-macrophage colony-stimulating factor...
  94. ncbi Evaluation of prostate-specific antigen declines for surrogacy in patients treated on SWOG 99-16
    Daniel P Petrylak
    Columbia University, New York, NY 10032, USA
    J Natl Cancer Inst 98:516-21. 2006
    ..We evaluated PSA changes as potential surrogate markers for survival by using data from a clinical trial...
  95. ncbi Clinical outcomes by age in men with hormone refractory prostate cancer: a pooled analysis of 8 Cancer and Leukemia Group B (CALGB) studies
    Susan Halabi
    Department of Biostatistics and Bioinformatics, Duke University Medical Center, 2424 Erwin Road, Durham, NC 27705, USA
    J Urol 176:81-6. 2006
    ..We determined if age is a prognostic factor of clinical outcomes, specifically overall survival, disease-free survival and progression-free survival in men with hormone refractory prostate cancer...
  96. ncbi Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: results of a phase I trial
    Roy S Herbst
    Department of Thoracic/Head and Neck Medical Oncology, University of Texas M.D. Anderson Cancer Center, Houston, TX, USA
    J Clin Oncol 20:3815-25. 2002
    ..Antitumor activity was observed at all doses. Pharmacokinetic analyses confirmed suitability of once-daily oral dosing...
  97. ncbi Maximal COX-2 immunostaining and clinical response to celecoxib and interferon alpha therapy in metastatic renal cell carcinoma
    Brian I Rini
    Department of Hematology and Oncology, Cleveland Clinic, Taussig Cancer Center, Cleveland, Ohio 44195, USA
    Cancer 106:566-75. 2006
    ..Based on potential additive or synergistic antitumor effects, interferon-alpha (IFNalpha) and celecoxib, an oral COX-2 inhibitor, were given to metastatic RCC patients in a Phase II trial...
  98. ncbi Combination immunotherapy with prostatic acid phosphatase pulsed antigen-presenting cells (provenge) plus bevacizumab in patients with serologic progression of prostate cancer after definitive local therapy
    Brian I Rini
    Department of Solid Tumor Oncology and Urology, Cleveland Clinic Taussig Cancer Center, Cleveland, Ohio 44195, USA
    Cancer 107:67-74. 2006
    ..A clinical trial was conducted to determine the prostate-specific antigen (PSA) and immunomodulatory effects of this combination immunotherapy...
  99. ncbi Androgen receptor mutations in androgen-independent prostate cancer: Cancer and Leukemia Group B Study 9663
    Mary Ellen Taplin
    University of Massachusetts Memorial Health Center, Department of Oncology, 55 Lake Ave North, Worcester, MA 01655, USA
    J Clin Oncol 21:2673-8. 2003
    ..Bone marrow specimens containing prostate tumor were obtained from men undergoing antiandrogen withdrawal for AR sequence analysis and clinical correlation. Materials and..
  100. ncbi A phase II study of estramustine, docetaxel, and carboplatin with granulocyte-colony-stimulating factor support in patients with hormone-refractory prostate carcinoma: Cancer and Leukemia Group B 99813
    William K Oh
    Lank Center for Geritourinary Oncology, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Cancer 98:2592-8. 2003
    ..The authors determined the safety and efficacy of estramustine, docetaxel, and carboplatin with granulocyte-colony-stimulating factor (G-CSF) support in patients with hormone-refractory prostate carcinoma...
  101. ncbi Multi-institutional randomized phase II trial of the epothilone B analog ixabepilone (BMS-247550) with or without estramustine phosphate in patients with progressive castrate metastatic prostate cancer
    Matthew D Galsky
    Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10021, USA
    J Clin Oncol 23:1439-46. 2005
    ..To evaluate the antitumor activity and safety of the epothilone B analog, ixabepilone, with or without estramustine phosphate (EMP), in chemotherapy-naive patients with progressive castrate metastatic prostate cancer...